Advances in Cancer Research最新文献_第2页

The transition and current pattern of drug therapy for advanced gastric cancer 晚期胃癌药物治疗的转变与现状

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 DOI: 10.53388/2023623001

R. Xue, Xin-Ran Song

引用次数: 0

Notch signaling pathway in pancreatic tumorigenesis. 胰腺肿瘤发生过程中的 Notch 信号通路。

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 Epub Date: 2023-02-28 DOI: 10.1016/bs.acr.2023.02.001

Wen-Cheng Chung, Keli Xu

{"title":"Notch signaling pathway in pancreatic tumorigenesis.","authors":"Wen-Cheng Chung, Keli Xu","doi":"10.1016/bs.acr.2023.02.001","DOIUrl":"10.1016/bs.acr.2023.02.001","url":null,"abstract":"The Notch signaling pathway is an evolutionary conserved signal transduction cascade that is critical to embryonic and postnatal development, but aberrant Notch signaling is also implicated in tumorigenesis of many organs including the pancreas. Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy in the pancreas, with a dismally low survival rate due to the late-stage diagnosis and peculiar therapeutic resistance. Upregulation of the Notch signaling pathway has been found in preneoplastic lesions as well as PDACs in genetically engineered mouse models and human patients, and inhibition of the Notch signaling suppresses tumor development and progression in mice as well as patient-derived xenograft tumor growth, suggesting a critical role for Notch in PDAC. However, the role of Notch signaling pathway remains contentious, exemplified by differential functions of Notch receptors and contrasting outcomes of abolishing Notch signaling in murine PDAC models with distinct cell-of-origin or at different stages. Glycosylation of Notch receptors represents a powerful regulatory mechanism of Notch signaling, and its functional significance in PDAC has begun to emerge. Beyond its impact on tumor cells, Notch signaling is an important regulator of the components of pancreatic tumor microenvironment, including blood vasculature, stellate cells, fibroblasts, and immune cells. Finally, Notch may act as a tumor suppressor in pancreatic neuroendocrine tumor, the second most common pancreatic neoplasm with the incidence on rise. This review summarizes the research on the complex roles of Notch signaling in pancreatic tumorigenesis and the development of potential Notch-targeting therapies for pancreatic cancer.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"159 ","pages":"1-36"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10000190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heparan sulfate proteoglycans in cancer: Pathogenesis and therapeutic potential. 硫酸肝素蛋白聚糖在癌症中的作用:发病机制和治疗潜力。

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 DOI: 10.1016/bs.acr.2022.08.001

Hua Yang, Lianchun Wang

{"title":"Heparan sulfate proteoglycans in cancer: Pathogenesis and therapeutic potential.","authors":"Hua Yang, Lianchun Wang","doi":"10.1016/bs.acr.2022.08.001","DOIUrl":"https://doi.org/10.1016/bs.acr.2022.08.001","url":null,"abstract":"The heparan sulfate proteoglycans (HSPGs) are glycoproteins that consist of a proteoglycan \"core\" protein and covalently attached heparan sulfate (HS) chain. HSPGs are ubiquitously expressed in mammalian cells on the cell surface and in the extracellular matrix (ECM) and secretory vesicles. Within HSPGs, the protein cores determine when and where HSPG expression takes place, and the HS chains mediate most of HSPG's biological roles through binding various protein ligands, including cytokines, chemokines, growth factors and receptors, morphogens, proteases, protease inhibitors, and ECM proteins. Through these interactions, HSPGs modulate cell proliferation, adhesion, migration, invasion, and angiogenesis to display essential functions in physiology and pathology. Under physiological conditions, the expression and localization of HSPGs are finely regulated to orchestrate their physiological functions, and this is disrupted in cancer. The HSPG dysregulation elicits multiple oncogenic signaling, including growth factor signaling, ECM and Integrin signaling, chemokine and immune signaling, cancer stem cell, cell differentiation, apoptosis, and senescence, to prompt cell transformation, proliferation, tumor invasion and metastasis, tumor angiogenesis and inflammation, and immunotolerance. These oncogenic roles make HSPGs an attractive pharmacological target for anti-cancer therapy. Several therapeutic strategies have been under development, including anti-HSPG antibodies, peptides and HS mimetics, synthetic xylosides, and heparinase inhibitors, and shown promising anti-cancer efficacy. Therefore, much progress has been made in this line of study. However, it needs to bear in mind that the roles of HSPGs in cancer can be either oncogenic or tumor-suppressive, depending on the HSPG and the cancer cell type with the underlying mechanisms that remain obscure. Further studies need to address these to fill the knowledge gap and rationalize more efficient therapeutic targeting.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"157 ","pages":"251-291"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10014758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The clinical role of glycobiology on ovarian cancer progression. 糖生物学在卵巢癌进展中的临床作用。

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 DOI: 10.1016/bs.acr.2022.07.004

Rhyisa Armbrister, Laura Ochoa, Karen L Abbott

引用次数: 1

Beyond glyco-proteomics-Understanding the role of genetics in cancer biomarkers. 超越糖蛋白组学——了解基因在癌症生物标志物中的作用。

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 DOI: 10.1016/bs.acr.2022.07.002

Andrew DelaCourt, Anand Mehta

{"title":"Beyond glyco-proteomics-Understanding the role of genetics in cancer biomarkers.","authors":"Andrew DelaCourt, Anand Mehta","doi":"10.1016/bs.acr.2022.07.002","DOIUrl":"https://doi.org/10.1016/bs.acr.2022.07.002","url":null,"abstract":"The development of robust cancer biomarkers is the most effective way to improve overall survival, as early detection and treatment leads to significantly better clinical outcomes. Many of the cancer biomarkers that have been identified and are clinically utilized are glycoproteins, oftentimes a specific glycoform. Aberrant glycosylation is a common theme in cancer, with dysregulated glycosylation driving tumor initiation and metastasis, and abnormal glycosylation can be detection both on the tissue surface and in serum. However, most cancer types are heterogeneous in regard to tumor genomics, and this heterogeneity extends to cancer glycomics. This limits the sensitivity of standalone glycan-based biomarkers, which has slowed their implementation clinically. However, if targeted biomarker development can take into account genomic tumor information, the development of complementary biomarkers that target unique cancer subgroups can be accomplished. This idea suggests the need for algorithm-based cancer biomarkers, which can utilize multiple biomarkers along with relevant demographic information. This concept has already been established in the detection of hepatocellular carcinoma with the GALAD score, and an algorithm-based approach would likely be effective in improving biomarker sensitivity for additional cancer types. In order to increase cancer diagnostic biomarker sensitivity, there must be more targeted biomarker development that considers tumor genomic, proteomic, metabolomic, and clinical data while identifying tumor biomarkers.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"157 ","pages":"57-81"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9292440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epigenetically programmed resistance to chemo- and immuno-therapies. 对化疗和免疫疗法的表观遗传学程序性耐药性。

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 Epub Date: 2023-01-27 DOI: 10.1016/bs.acr.2022.12.001

Reddick R Walker, Zainab Rentia, Katherine B Chiappinelli

引用次数: 0

Renal granuloma misdiagnosed as renal papillary carcinoma: a case report 肾肉芽肿误诊为肾乳头状癌1例

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 DOI: 10.53388/2023623011

Zengni Hu, Nian-yu Xue, Sheng-Min Zhang

引用次数: 0

Sarcopenia affects the treatment and prognosis of colorectal cancer 骨骼肌减少症影响结直肠癌的治疗和预后

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 DOI: 10.53388/2023623004

Neng-Liang Zhang, Chun-Lei Qian, Jian-Hua Wang

引用次数: 0

Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies. 靶向胰腺癌 KRAS：新的治疗策略

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 Epub Date: 2023-03-09 DOI: 10.1016/bs.acr.2023.02.004

Sajid Khan, Vivekananda Budamagunta, Daohong Zhou

{"title":"Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.","authors":"Sajid Khan, Vivekananda Budamagunta, Daohong Zhou","doi":"10.1016/bs.acr.2023.02.004","DOIUrl":"10.1016/bs.acr.2023.02.004","url":null,"abstract":"KRAS, a predominant member of the RAS family, is the most frequently mutated oncogene in human pancreatic cancer (∼95% of cases). Mutations in KRAS lead to its constitutive activation and activation of its downstream signaling pathways such as RAF/MEK/ERK and PI3K/AKT/mTOR that promote cell proliferation and provide apoptosis evasion capabilities to cancer cells. KRAS had been considered 'undruggable' until the discovery of the first covalent inhibitor targeting the G12C mutation. While G12C mutations are frequently found in non-small cell lung cancer, these are relatively rare in pancreatic cancer. On the other hand, pancreatic cancer harbors other KRAS mutations such as G12D and G12V. The inhibitors targeting G12D mutation (such as MRTX1133) have been recently developed, whereas those targeting other mutations are still lacking. Unfortunately, KRAS inhibitor monotherapy-associated resistance hinders their therapeutic efficacy. Therefore, various combination strategies have been tested and some yielded promising results, such as combinations with receptor tyrosine kinase, SHP2, or SOS1 inhibitors. In addition, we recently demonstrated that the combination of sotorasib with DT2216 (a BCL-XL-selective degrader) synergistically inhibits G12C-mutated pancreatic cancer cell growth in vitro and in vivo. This is in part because KRAS-targeted therapies induce cell cycle arrest and cellular senescence, which contributes to therapeutic resistance, while their combination with DT2216 can more effectively induce apoptosis. Similar combination strategies may also work for G12D inhibitors in pancreatic cancer. This chapter will review KRAS biochemistry, signaling pathways, different mutations, emerging KRAS-targeted therapies, and combination strategies. Finally, we discuss challenges associated with KRAS targeting and future directions, emphasizing pancreatic cancer.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"159 ","pages":"145-184"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9650726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oncogenic signaling pathways in pancreatic ductal adenocarcinoma. 胰腺导管腺癌的致癌信号通路。

2区医学

Advances in Cancer Research Pub Date : 2023-01-01 Epub Date: 2023-03-23 DOI: 10.1016/bs.acr.2023.02.006

Rahul Agrawal, Kedar Nath Natarajan

{"title":"Oncogenic signaling pathways in pancreatic ductal adenocarcinoma.","authors":"Rahul Agrawal, Kedar Nath Natarajan","doi":"10.1016/bs.acr.2023.02.006","DOIUrl":"10.1016/bs.acr.2023.02.006","url":null,"abstract":"Pancreatic ductal adenocarcinoma (PDAC) is the most common (∼90% cases) pancreatic neoplasm and one of the most lethal cancer among all malignances. PDAC harbor aberrant oncogenic signaling that may result from the multiple genetic and epigenetic alterations such as the mutation in driver genes (KRAS, CDKN2A, p53), genomic amplification of regulatory genes (MYC, IGF2BP2, ROIK3), deregulation of chromatin-modifying proteins (HDAC, WDR5) among others. A key event is the formation of Pancreatic Intraepithelial Neoplasia (PanIN) that often results from the activating mutation in KRAS. Mutated KRAS can direct a variety of signaling pathways and modulate downstream targets including MYC, which play an important role in cancer progression. In this review, we discuss recent literature shedding light on the origins of PDAC from the perspective of major oncogenic signaling pathways. We highlight how MYC directly and indirectly, with cooperation with KRAS, affect epigenetic reprogramming and metastasis. Additionally, we summarize the recent findings from single cell genomic approaches that highlight heterogeneity in PDAC and tumor microenvironment, and provide molecular avenues for PDAC treatment in the future.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"159 ","pages":"251-283"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9653444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1